TGTX Price Prediction Next Week
Analysis and Insights
Fundamental Analysis:
TG Therapeutics (TGTX) has shown strong performance recently, driven by the success of its product Briumvi, which saw a 200% year-over-year increase in sales to $313 million. The company is targeting $540 million in sales for this year, indicating high growth potential. Earnings estimates for the upcoming quarter have been revised 127.5% higher, suggesting strong investor confidence.
Technical Analysis:
The stock is currently trading at $40.94 with a bullish trend. Key technical indicators include:
- RSI (6-period): 79.33, indicating overbought conditions but still in an uptrend.
- MACD: Positive at 2.04, showing strong upward momentum.
- Fibonacci Levels: Resistance at $40.82 and $43.55, with support at $36.40.
Options Activity:
Bullish options activity has been observed, with 2,450 calls traded and increasing implied volatility to 63.04%. This indicates strong investor interest ahead of earnings on May 8th.
Conclusion:
Given the strong fundamentals, positive earnings revisions, and bullish options activity, the stock is expected to continue its upward trend. However, the overbought RSI suggests a potential short-term pullback. The next resistance level at $43.55 is a key target.
Prediction: The stock price is expected to reach $43.20 in the next trading week. Buy recommendation, as the overall trend remains bullish despite minor corrections.
TGTX Similar Chart Price Prediction
The price of TGTX is predicted to go up -21.26%, based on the high correlation periods with DMAC. The similarity of these two price pattern on the periods is 96.82%.
TGTX
DMAC
Down: -21.26%Similarity: 96.82%
TGTX Revenue Forecast
TGTX EPS Forecast
TGTX FAQs
What is TGTX revenue forecast for next quarter？
TGTX Analyst's Forecast
Eric Joseph
JP Morgan
Buy
2024-11-25
Price Target
$30 → $43
Upside
+24.24%
JPMorgan raised the firm's price target on TG Therapeutics to $43 from $30 and keeps an Overweight rating on the shares. The firm says that with a potential SC Briumvi formulation coming into view beginning in the first half of 2025, it updated TG's model to reflect risk adjusted Briumvi forecasts within the at-home/self-administered anti-CD20 segment of relapsing multiple sclerosis. At $3.5B, the analyst's peak Briumvi SC forecast assumes market entry beginning in 2028 and ultimately garnering 35% share of the self-administered CD20 segment. JPMorgan sees an increasingly attractive setup to TG shares in the mid-term.
Tara Bancroft
TD Cowen
Strong Buy
2024-10-29
Price Target
$50
Upside
+94.48%
